Compare California Nanotechnologies Corp. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
CAD 15 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.01
-120.99%
4.90
Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Nov 2025)
Net Profit:
-2 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-12.9%
0%
-12.9%
6 Months
-18.18%
0%
-18.18%
1 Year
-61.97%
0%
-61.97%
2 Years
-29.87%
0%
-29.87%
3 Years
145.45%
0%
145.45%
4 Years
237.5%
0%
237.5%
5 Years
157.14%
0%
157.14%
California Nanotechnologies Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
31.16%
EBIT Growth (5y)
-211.20%
EBIT to Interest (avg)
0.62
Debt to EBITDA (avg)
1.05
Net Debt to Equity (avg)
-0.09
Sales to Capital Employed (avg)
2.30
Tax Ratio
24.17%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
39.85%
ROE (avg)
25.88%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.90
EV to EBIT
-5.18
EV to EBITDA
-8.05
EV to Capital Employed
4.95
EV to Sales
3.41
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-95.41%
ROE (Latest)
-120.99%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Nov'25 - QoQ
Nov'25
Aug'25
Change(%)
Net Sales
0.50
1.10
-54.55%
Operating Profit (PBDIT) excl Other Income
-0.90
-0.20
-350.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.20
-100.00%
Consolidate Net Profit
-1.50
-0.40
-275.00%
Operating Profit Margin (Excl OI)
-2,105.40%
-450.60%
-165.48%
USD in Million.
Net Sales
QoQ Growth in quarter ended Nov 2025 is -54.55% vs 10.00% in Aug 2025
Consolidated Net Profit
QoQ Growth in quarter ended Nov 2025 is -275.00% vs 33.33% in Aug 2025
Annual Results Snapshot (Consolidated) - Feb'25
Feb'25
Feb'24
Change(%)
Net Sales
8.60
4.50
91.11%
Operating Profit (PBDIT) excl Other Income
2.70
1.10
145.45%
Interest
0.30
0.10
200.00%
Exceptional Items
-1.70
-0.20
-750.00%
Consolidate Net Profit
-0.20
0.50
-140.00%
Operating Profit Margin (Excl OI)
222.00%
190.30%
3.17%
USD in Million.
Net Sales
YoY Growth in year ended Feb 2025 is 91.11% vs 150.00% in Feb 2024
Consolidated Net Profit
YoY Growth in year ended Feb 2025 is -140.00% vs 400.00% in Feb 2024
About California Nanotechnologies Corp. 
California Nanotechnologies Corp.
Pharmaceuticals & Biotechnology
California Nanotechnologies Corp. is engaged in the development of nanocrystalline materials through grain size reduction. The Company focuses on commercialization efforts. It targets various markets, such as consumer electronics, aerospace, defense, automotive, oil and gas, medical, and sports and recreation. It supplies thermal spray powders that are utilized for wear, corrosion and thermal barrier coatings. Powders are available for plasma, high velocity oxygen fuel (HVOF) and particle tracking analysis (PTA) welding. Its Spark Plasma Sintering (SPS) allows for the application of temperature and pressure through high-density pulsed current within a controlled atmosphere. SPS applications include semiconductors, fine ceramics, thermoelectrics, electronics, nanophases, hard alloy tools, biomaterials, porous materials and molds and dies. To provide its products, the Company has an array of production facilities, including cold forging, cryogenic milling and spray drying.
Company Coordinates 
Company Details
17220 Edwards Rd , CERRITOS CA : 90703-2426
Registrar Details






